Skip to content

Penumbra PEN Additional Paid-In Capital

Additional Paid-In Capital at other companies

Medtronic logo
MedtronicMDT
$20.93B+0.4%

Other financials

Income statement

See full
Revenue$374.8M+15.6%
Gross profit$253.4M+17.4%
Operating income$38.2M-5.2%
Net income$32.6M-16.9%
EPS (diluted)$0.82-18.0%

Balance sheet

See full
Cash & equivalents$241.3M-35.8%
Total debt$216.2M-2.0%
Total equity$1.5B+21.5%
Total assets$1.9B+19.2%

Cash flow

See full
Operating cash flow$87.0M+77.6%
CapEx$13.7M+1.5%
Free cash flow$73.3M+106%

Valuation

See full
Market cap$12.48B+25.1%
Enterprise value$12.45B+26.8%
P/E72.9×-163×
P/S8.6×+0.5×

Profitability

See full
Gross margin67.4%+3.7pp
Operating margin12.9%+9.8pp
Net margin11.8%+8.4pp
FCF margin14.6%+2.5pp

Returns & leverage

See full
Return on equity12.7%+9.2pp
Debt / equity0.1×0.0×
Current ratio-0.3×

Where this comes from

Reported directly by Penumbra in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Penumbra’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Penumbra's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Penumbra's additional paid-in capital?
Penumbra (PEN) reported additional paid-in capital of $1.2B in Q1 2026.
How has Penumbra's additional paid-in capital changed year-over-year?
Penumbra's additional paid-in capital increased by 7.6% year-over-year, from $1.12B to $1.2B.
What is the long-term trend for Penumbra's additional paid-in capital?
Over 5 years (2020 to 2025), Penumbra's additional paid-in capital has grown at a 14.7% compound annual growth rate (CAGR), from $598.3M to $1.19B.
What does additional paid-in capital mean?
The surplus capital contributed by investors above the nominal par value of shares.
How do you interpret additional paid-in capital?
A growing balance often indicates successful equity financing rounds or significant stock-based compensation expenses.
How does additional paid-in capital compare across companies?
High levels of additional paid-in capital are common in high-growth medical device firms that rely on equity to fund R&D and expansion.